What is the 13F Pro Quality Score for ADCT?

13F Pro ranks ADC Therapeutics SA (ADCT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ADCT's current score at https://13fpro.ai/research/ADCT (free sign-up required for the full ranking).

Which hedge funds own the most ADCT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ADCT include Redmile Group,, TCG Crossover Management,, Prosight Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ADCT as soon as new 13F filings post.

Where does 13F Pro source ADCT data?

All ADC Therapeutics SA fundamentals and ownership data come directly from SEC EDGAR. ADC Therapeutics SA files with the SEC under CIK 1771910. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ADCT in?

ADC Therapeutics SA (ADCT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ADCT research updated on 13F Pro?

ADCT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ADC Therapeutics SA(ADCT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1771910 ADCT stock profile & AI dashboard →

13F Pro Quality Score

16.3/100

Rank #2,739 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

34.3/100

Profitability

5.1/100

Balance Sheet

3.1/100

Earnings Quality

30.0/100

Free Cash Flow

5.1/100

Institutional Flow

53.3/100

Revenue Scale

14.2/100

Dilution Risk

18.8/100

ADCT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ADC Therapeutics SA (ADCT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADCT at 16.3/100 on a 32-signal composite quality model, placing it at rank #2,739 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (3.1) and profitability (5.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ADC Therapeutics SA reports quarterly revenue of $20.9M, net income of $-33.0M, free cash flow of $-29.7M. Top institutional holders of ADCT by reported 13-F value include Redmile Group,, TCG Crossover Management,, Prosight Management,, based on the most recent SEC filings. ADCT trades on the NYSE exchange and files with the SEC under CIK 1771910. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADC Therapeutics SA directly from SEC EDGAR. ADC Therapeutics SA's 13F Pro composite quality score has ranged between 8 and 40 since 2026, currently 16.3 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.

Revenue

Q1 2026

$20.9M

Net Income

Q1 2026

$-33.0M

Free Cash Flow

Q1 2026

$-29.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+14.9% YoY

$81.4MFY 2025

FY23 $69.6MFY24 $70.8MFY25 $81.4M

Net Income

+9.6% YoY

$-142.6MFY 2025

FY23 $-240.1MFY24 $-157.8MFY25 $-142.6M

Operating Income

+7.0% YoY

$-121.5MFY 2025

FY23 $-166.0MFY24 $-130.7MFY25 $-121.5M

EPS (Diluted)

+30.9% YoY

$-1.12FY 2025

FY23 $-2.94FY24 $-1.62FY25 $-1.12

Total Assets

+0.4% YoY

$323.1MFY 2025

FY23 $354.8MFY24 $322.0MFY25 $323.1M

Total Debt

$3.0MFY 2025

FY23 —FY24 $0.00FY25 $3.0M

Op. Cash Flow

-14.0% YoY

$-141.2MFY 2025

FY23 $-118.7MFY24 $-123.8MFY25 $-141.2M

Metric	FY 2025	FY 2024	FY 2023
Revenue	$81.4M +14.9%	$70.8M +1.8%	$69.6M
Net Income	$-142.6M +9.6%	$-157.8M +34.3%	$-240.1M
Operating Income	$-121.5M +7.0%	$-130.7M +21.3%	$-166.0M
EPS (Diluted)	$-1.12 +30.9%	$-1.62 +44.9%	$-2.94
Total Assets	$323.1M +0.4%	$322.0M -9.2%	$354.8M
Total Debt	$3.0M	$0.00	—
Operating Cash Flow	$-141.2M -14.0%	$-123.8M -4.3%	$-118.7M

AI Insight: ADCT Financial Trends

ADCT showed revenue volatility around $16-23M with persistent losses, though Q4 2025 net loss narrowed dramatically to -$6M from typical -$30-50M range.

• Revenue fluctuated between $16M-$23M with no clear growth trend over 8 quarters from Q2 2024 to Q1 2026.

• Net loss improved significantly to -$6M in Q4 2025 from -$41M in Q3 2025, best result in the period.

• Operating loss narrowed from -$31M in Q3 2025 to -$18M in Q4 2025, showing operational improvement.

⚠ Net loss widened back to -$33M in Q1 2026 after Q4 2025's improved -$6M result, questioning sustainability.

⚠ Negative equity deteriorated from -$132M in Q2 2024 to -$216M in Q1 2026, indicating capital structure stress.

AI Insight: ADCT Ratio Trends

ADCT's operating margin improved dramatically to -77.7% in Q4 2025 from prior quarters averaging around -190%, but deteriorated again to -121.1% in Q1 2026.

• Operating margin improved sharply from -188.5% in Q3 2025 to -77.7% in Q4 2025, then worsened to -121.1% in Q1 2026.

• Net profit margin showed similar volatility, improving from deeply negative levels to -27.8% in Q4 2025 before declining to -158.1% in Q1 2026.

• ROA improved from -56.5% in Q3 2025 to -7.9% in Q4 2025, then deteriorated to -45.2% in the latest quarter.

⚠ Extreme quarterly volatility in profitability metrics suggests unstable operational performance or significant one-time items affecting results.

⚠ All profitability metrics remain deeply negative despite Q4 2025 improvement, indicating continued cash burn and operational challenges.

Get alerted when ADCT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ADC Therapeutics SA including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ADCT

Redmile Group, LLC
$58.0M15,470,502 sh
TCG Crossover Management, LLC
$42.7M11,390,175 sh
Prosight Management, LP
$31.1M8,300,000 sh
BlackRock, Inc.
$23.4M6,250,747 sh
EVENTIDE ASSET MANAGEMENT, LLC
$21.4M5,701,655 sh
Nantahala Capital Management, LLC
$21.0M5,597,433 sh
MORGAN STANLEY
$14.3M3,812,582 sh
Point72 Asset Management, L.P.
$12.7M3,382,129 sh
MILLENNIUM MANAGEMENT LLC
$11.7M3,119,154 sh
GOLDMAN SACHS GROUP INC
$6.2M1,653,026 sh

Fund	Value	Shares
Redmile Group, LLC	$58.0M	15,470,502
TCG Crossover Management, LLC	$42.7M	11,390,175
Prosight Management, LP	$31.1M	8,300,000
BlackRock, Inc.	$23.4M	6,250,747
EVENTIDE ASSET MANAGEMENT, LLC	$21.4M	5,701,655
Nantahala Capital Management, LLC	$21.0M	5,597,433
MORGAN STANLEY	$14.3M	3,812,582
Point72 Asset Management, L.P.	$12.7M	3,382,129
MILLENNIUM MANAGEMENT LLC	$11.7M	3,119,154
GOLDMAN SACHS GROUP INC	$6.2M	1,653,026

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ADCT on your watchlist

Track score changes the day ADC Therapeutics SA files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ADCT a good stock to buy?

13F Pro's AI-powered analysis of ADC Therapeutics SA (ADCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ADCT are available on the ADCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ADCT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ADCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ADC Therapeutics SA's investment landscape.